FDA Fully Approves Tivdak for Recurrent or Metastatic Cervical Cancer
The FDA has granted traditional approval to tisotumab vedotin-tftv (Tivdak, Seagen [now part of Pfizer]) for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Tisotumab vedotin-tftv previously received accelerated approval for this indication.